Scaling Up for First Product Launch: Seven Hazards to Avoid Pierre Jacquet, M.D., Ph.D. Peter Rosenorn Aditya Natarajan Read more
Related Practice Life Sciences & Pharma As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for that first launch. 06192019150626
Article Diagnostic & Ancillary Provider & Service Digital Transformation of the Laboratory April 21, 2023
Executive Insights Biotech and Pharmaceuticals Shareholder Value Creation for First-Time Launchers: Two Decades of Learnings December 30, 2022
Published Articles Mental and Behavioral Health Trip or No Trip? The Diverging Development of Psychedelic Drugs for Mental Health … December 15, 2022